1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Nasdaq told Expensify on May 28, 2026 that the company has regained compliance with the $1.00 minimum bid price requirement and that the matter is closed. The Class A stock closed at $1.00 or higher for the 10 consecutive business days from May 13 to May 27, 2026, resolving a deficiency notice received April 17, 2026.
Nasdaq deficiency notice received April 17, 2026 for closing bid price below $1.00 for 30 consecutive business days
Nasdaq confirmed on May 28, 2026 that the stock closed at $1.00 or higher from May 13 to May 27, 2026
Nasdaq considers the minimum bid price matter closed
Otter Tail's subsidiaries agreed on May 28, 2026 to settle antitrust claims from two of three putative classes in the PVC Pipe Antitrust Litigation, with total payments of $73.5 million. The company says it does not admit wrongdoing and expects to fund the payments from available cash, which it says is not expected to have a material adverse effect on its financial position or liquidity. Claims from the End-User Class remain pending, and the settlements require court approval.
Settlements with the Direct Purchaser Class ($39.5 million) and Non-Converter Seller Purchaser Class ($34.0 million) were signed May 28, 2026.
Payments will be made by subsidiaries Northern Pipe Products, Inc. and Vinyltech Corporation, about 21 days after preliminary court approval.
Claims by the End-User Class remain pending in the Northern District of Illinois.
The company says the settlements are not expected to have a material adverse effect on its financial position or liquidity.
On May 20, 2026, A SPAC III Acquisition Corp. received a Nasdaq letter stating its stockholders' equity, as reported for the quarter ended March 31, 2026, was below the $2,500,000 minimum required for continued listing. The company has 45 calendar days to submit a compliance plan, and Nasdaq can grant up to 180 days if it accepts the plan, but the filing says there is no assurance the company will regain compliance or that Nasdaq will accept its plan.
Nasdaq letter received May 20, 2026, citing Listing Rule 5550(b)(1) and the $2,500,000 minimum stockholders' equity requirement
Company has 45 calendar days to submit a plan to regain compliance
If accepted, Nasdaq can extend compliance time by up to 180 calendar days from the letter date
Company says it is working on a compliance plan; no assurance of regaining compliance is given
Focus Universal said it believes it has stockholders' equity of at least $2.5 million, the level required for continued Nasdaq Capital Market listing. The company cites the conversion of most Series B preferred stock into common stock, the redemption of the remaining preferred shares, and the exercise of pre-funded warrants issued in an April 2026 private placement. The filing reflects a compliance position rather than a change in operating results.
Company believes stockholders' equity is at least $2.5 million, meeting Nasdaq Listing Rule 5550(b)(1)
Series B Conversion of 5,216 preferred shares into 665,328 common shares, notified around April 6, 2026
Remaining Series B preferred redeemed from Great Point Capital LLC for $961,860 under an April 13, 2026 agreement
Pre-Funded Warrant for 1,117,318 shares from the $4,000,000 Armistice Capital placement has been fully exercised
MasterCraft agreed to pay $425,000 in attorneys' fees and expenses to settle a Delaware stockholder lawsuit challenging a stockholders agreement provision on director removal. The provision was removed in March 2026, which mooted the claims, and the Court of Chancery closed the case on May 19, 2026, without reviewing the fee payment.
Plaintiff Bruce Taylor filed a putative class action on February 11, 2026, in Delaware Court of Chancery.
The challenged provision was removed by a stockholders agreement amendment dated March 11, 2026.
MasterCraft agreed to pay $425,000 in attorneys' fees and expenses in full settlement of plaintiff's fee claims.
The Court entered an order closing the action on May 19, 2026.
Bioventus disclosed that the FDA issued a final order on April 16, 2026 reclassifying non-invasive bone growth stimulators, including its Exogen Ultrasound Bone Healing System, from Class III to Class II devices. CMS also updated billing requirements and the Medicare fee schedule for these devices for dates of service on or after May 18, 2026, and the company reiterated its 2026 financial guidance, though it said further CMS changes could require a revised outlook.
FDA final order dated April 16, 2026 reclassified bone growth stimulators from Class III to Class II
CMS updated billing requirements and Medicare fee schedule under HCPCS codes E0747, E0748, and E0760 for dates of service on or after May 18, 2026
Bioventus does not presently expect reimbursement rate changes to have a material impact on 2026 results and reiterated its 2026 guidance
Future CMS changes to Exogen Medicare reimbursement rates could require a revised financial outlook
VenHub Global received a Nasdaq letter on May 21, 2026, confirming it has regained compliance with the $1.00 minimum closing bid price rule and that the matter is closed. The company's common stock closed at or above $1.00 for 10 consecutive business days from May 7 to May 20, 2026, removing a near-term risk of delisting from Nasdaq.
Nasdaq Listing Rule 5450(a)(1) compliance regained, per letter dated May 21, 2026
Compliance measured over 10 consecutive business days, May 7 to May 20, 2026, with closing bid at or above $1.00
Nasdaq has closed the matter; the filing does not describe any financial results or other terms
Hub Group received a Nasdaq notice that it is not in compliance with listing rules because it did not timely file its Form 10-Q for the quarter ended March 31, 2026, which follows its delayed 2025 Form 10-K. The notice has no immediate effect on the listing or trading of its Class A common stock, but the company is restating prior financial statements and must file its overdue reports by September 14, 2026 to avoid further listing action.
Nasdaq notice dated May 19, 2026 cites Listing Rule 5250(c)(1) for the late Q1 2026 Form 10-Q.
Nasdaq's exception period runs until September 14, 2026 for the company to regain compliance.
An updated compliance plan is due to Nasdaq by June 3, 2026.
Restatements cover 2024 and 2023 annual periods and the 2025 quarters ended March 31, June 30 and September 30.
Kentucky American Water, a wholly owned subsidiary, filed a request with the Kentucky Public Service Commission on May 15, 2026 seeking $17.7 million in aggregate annualized incremental revenue, with interim rates proposed from December 16, 2026 and subject to refund. The request is driven mainly by about $108 million of capital to be invested in 2027, and the rate case is expected to conclude by the end of the first quarter of 2027. At the May 13, 2026 annual meeting, shareholders also elected all 10 director nominees and approved several compensation plan and charter amendments.
Requested incremental revenue of $17.7 million, based on a proposed 10.75% return on equity and a 52.29% common equity component.
Interim rates proposed to begin December 16, 2026, subject to refund; the general rate case is expected to be completed by the end of Q1 2027.
At the May 13, 2026 annual meeting, all 10 director nominees were elected, with 177,886,133 shares (91.1%) represented.
Officer exculpation charter amendment took effect May 14, 2026; amended equity and employee stock purchase plans are effective January 1 and February 5, 2027.
Hub Group said its Audit Committee concluded on May 11, 2026 that its audited financial statements for 2024 and 2023 were materially misstated and should no longer be relied upon. The company said a review found transactions that were prematurely or incorrectly recognized or not adequately supported, and it expects to conclude that internal controls were not effective for both years, which matters to shareholders because prior results and reports can no longer be trusted until restated.
Audit Committee concluded on May 11, 2026 that the 2024 and 2023 audited financial statements were materially misstated
Affected annual reports were the Form 10-K filed February 25, 2025 (2024) and February 27, 2024 (2023)
Company expects to conclude that disclosure controls and internal control over financial reporting were not effective in 2024 and 2023
Ernst & Young LLP, the independent registered public accounting firm, was briefed on the matters
Cryo-Cell International received written notice on May 6, 2026 that NYSE Regulation accepted its plan to regain compliance with NYSE American continued listing standards. The company's common stock will keep trading on NYSE American during a plan period ending September 9, 2027, but the company says it cannot assure it will regain compliance by then, and NYSE American may begin delisting proceedings if it does not.
NYSE Regulation accepted the compliance plan the company submitted on April 8, 2026, and granted a plan period through September 9, 2027.
The deficiencies cited are a stockholders' deficit as of November 30, 2025, and net losses in two of the three most recent fiscal years.
Common stock continues to be listed and traded on NYSE American, subject to the plan's initiatives and periodic review.
If the company fails to regain compliance by the deadline or make progress under the plan, NYSE American may initiate delisting proceedings.
Nasdaq told Versus Systems on April 29, 2026 that it did not meet the $2.5 million minimum stockholders' equity required for continued listing, citing equity of $1,918,303 at December 31, 2025. The company has until June 13, 2026 to submit a compliance plan, and Nasdaq may extend the deadline to October 26, 2026 if the plan is accepted, so the letter has no immediate effect on the listing.
Nasdaq deficiency letter dated April 29, 2026 cites stockholders' equity of $1,918,303 versus the $2,500,000 minimum
Compliance plan due June 13, 2026; possible extension to October 26, 2026 if accepted
Planned sale of 1,513,128 shares to ASPIS Cyber Technologies for $1,700,000 at $1.1235 per share, expected to close on or before May 14, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.